key: cord-0909694-y8xwd25k
authors: Khurshid, Z.; Zohaib, S.; Joshi, C.; Moin, S. F.; Zafar, M. S.; Speicher, D. J.
title: Saliva as a non-invasive sample for the detection of SARS-CoV-2: a systematic review
date: 2020-05-13
journal: nan
DOI: 10.1101/2020.05.09.20096354
sha: 82fff12162074c85970f58277accf679cf261344
doc_id: 909694
cord_uid: y8xwd25k

The accepted gold standard for diagnosing coronavirus disease (COVID-19) is the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA from nasopharyngeal swabs (NPS). However, shortage of reagents has made NPS collection challenging, and alternative samples need to be explored. Due to its non-invasive nature, saliva has considerable diagnostic potential. Therefore, to guide diagnostic laboratories globally, we conducted a systematic review to determine the utility of saliva for the detection of SARS-CoV-2. A systematic search of major databases (PubMed, ISI Web of Science, Scopus, and Google Scholar) was performed to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. There was a total of 10 publications that fit the criteria for review. Most studies collected drooled whole saliva from hospitalized patients or pipetted saliva from intubated patients. Saliva was positive in 31-92% of patients depending on the cohort and length of hospitalization. Viral loads in saliva are comparable to those in NPS and ranged from 9.9 x 10^2 to 1.2 x 10^8 copies/mL during the first week of symptoms and decrease over time. Saliva can be positive up to 20 days post-symptom onset with viral loads correlating with symptom severity and degree of tissue damage. Based on these findings, we made suggestions to guide the clinical laboratory and suggest the need for diagnostic accuracy studies for the detection of SARS-CoV-2 from saliva.

The coronavirus disease pandemic has affected the entire world, especially the most vulnerable population (i.e. the elderly living in nursing homes). The high demand of nasopharyngeal swabs (NPS), and the low supply of laboratory reagents and test kits highlight the need for alternative methods to facilitate accurate universal screening of COVID-19. The aetiological agent of COVID-19 is the novel Betacoronavirus, subgenus Sarbecovirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in Hubei Province, China (1, 2) . SARS-CoV-2 is a large, roughly spherical, enveloped virus, with a non-segmented positive-sense strand RNA genome ~30 kb in length (3) . Since the initial outbreak, clinical symptoms have ranged from mild to severe atypical pneumonia with the disease spreading through human-to-human transmission (1) . With an estimated incubation period of 5.1 days, and less than 2.5% of individuals displaying symptoms within 2.2 days of exposure, asymptomatic spread is possible, especially in children and healthy adults (4) . The community transmission of SARS-CoV-2, especially asymptomatic spread, can be detrimental to both acute care hospitals and community settings, such as nursing homes. Therefore, robust diagnostics algorithms for SARS-CoV-2 are essential to quarantine infected individuals to prevent the spread of disease.

The current gold standard to detect SARS-CoV-2 RNA is by reverse transcription real-time polymerase chain reaction (RT-rtPCR) in NPS. NPS is invasive to collect, and due to widespread universal testing and a huge strain on supply lines, alternative diagnostic algorithms are needed (5) (6) (7) . Saliva has considerable diagnostic potential: it is non-invasive, abundant, easily collected, and representative of oral and systemic health (8) . The use of saliva looks promising as SARS-CoV-2 RNA is present in saliva with loads and sensitivity comparable to NPS (9) (10) (11) . However, . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.09.20096354 doi: medRxiv preprint salivary endonucleases make proper sample handling critical for accurate testing (12) . Therefore, we conducted a systematic review to evaluate the potential of using saliva for the detection of SARS-CoV-2 and make suggestions for the clinical diagnostic labotatory.

This scoping review follows the guidelines of Preferred Reporting Items for Systematic Reviews and Metanalysis (PRISMA). A systematic search was performed on four major databases (PubMed, ISI Web of Science, Scopus, and Google Scholar) by two independent reviewers to identify articles published in English prior to April 25, 2020 to answer, "Can saliva be used for to detect SARS-CoV-2 and diagnose COVID-19?" The systematic search was performed using the following Medical Subject Headings (MeSH) terms and keywords: "COVID-19" OR "COVID-2019" OR "severe acute respiratory syndrome coronavirus 2" OR "2019-nCoV" OR "SARS-CoV-2" AND "saliva". Manuscripts were included if they aligned with the following PECOS (Patient, Exposure, Comparator and Outcome) guidelines: (P) male or female of any age group visiting the Emergency Department; (E) SARS-CoV-2 infected; (C) Systematically healthy patients as control;

(O) salivary viral load. Manuscripts were excluded if they were letters to the editor, perspectives or review papers. Given the explosion of new research, preprints were included from BioRxiv and medRxiv if the inclusion criteria were met. Both reviewers mutually agreed to use the same inclusion and exclusion criteria for the search, and disagreements were resolved by discussion.

Ethics approval was not required.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 13, 2020. 

Data extraction was performed independently by two investigators and confirmed by a third. Each study was examined for saliva sampling protocol, nucleic acid extraction procedure, SARS-CoV-2 detection, and primary findings. Discrepancies were resolved by consensus.

We identified 25 potential articles from database searches that investigated the detection of SARS-CoV-2 in saliva ( Figure 1 ). After removing the duplicates and reviewing the abstracts for inclusion and exclusion criteria, the full-text of 10 papers were scrutinized for this systematic review.

Studies were from China (n=10), Italy (n=2), USA (n=1) and South Korea (n=1). Apart from case reports, studies enrolled hospitalized patients and compared saliva to NPS for the initial diagnosis and viral load monitoring. Apart for two studies, study cohorts were small (range: 12-44) with a relatively equal number of males and females with an average age of 61 years (range: 18-92 years) ( Table 1 ). The specimen collected varied by study and included saliva (n=6), sputum or deep saliva (n=4), and oropharyngeal swabs (OPS, n=3). No study revealed transportation or storage conditions. There is great variation in the extraction and amplification kits used, but most extractions were performed manually with commercial spin columns (n=6), and two studies did automated extraction with the NucliSENS ® easyMag ® (9, 13) . PCR amplification was performed with a mix of lab-developed tests (LDT, n=6) and commercial assays (n=4) targeting a wide range of genes.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 13, 2020. 

Despite the heterogeneity of oral samples used, based on these limited studies, it is evident that saliva is comparable, if not superior to NPS for initial detection of SARS-CoV-2 upon hospitalization and is more consistent for monitoring viremia. In most comparative studies, drooled saliva had higher positivity rates than deep saliva/sputum and was useful from initial screening to intubation. Positivity of saliva was 31-92% depending on the cohort and length of hospitalization. Viral load in saliva was highest during the first week of symptom onset, ranging from 9.9 × 10 2 to 1.2 × 10 8 copies/mL, and then gradually declined (9, 14) . At initial screening viral loads and positivity rates were comparable to NPS, but one study found salivary loads were five-times higher than in NPS (15) . Higher salivary viral loads were also found in patients with more severe disease (16) and correlated to tissue damage (17). In a study screening 98 asymptomatic health care workers all NPS were negative, but two were positive in saliva (15) .

Studies monitoring viral loads reported that initially saliva was comparable to NPS, but over time NPS became negative while saliva remained positive up to 20 days post-symptom onset, even after respiratory symptoms became negative. However, after the first week positivity rates in saliva decreased, and positivity in anal swabs increased, suggesting a possible shift in viral infection as disease progresses (18) .

Initial studies examining the utility of saliva for the detection of SARS-CoV-2 RNA are comparable, if not superior to NPS for screening and monitoring viral loads. With NPS reagents increasingly in short supply, saliva is a possible alternative sample for diagnostic algorithms.

Infectious cell-free SARS-CoV-2 virion is transmitted in salivary droplets by infected people breathing, talking, coughing, or sneezing in close contact and infecting another nearby person . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.09.20096354 doi: medRxiv preprint through the mouth, nose or eyes (10) . SARS-CoV-2 infects human epithelial cells through the host cell receptor angiotensin-converting enzyme II (ACE2), which is expressed on cells lining the lungs, oral buccal and gingiva (19) . This infectious virion is both detectable in saliva and culturable on Vero E6 cells making saliva both a non-invasive sample that is easy to collect but also a potential exposure risk for front-line healthcare workers (9) . SARS-CoV-2 has been detected in a variety of oral samples, including whole saliva, oral swabs, oropharyngeal swabs, and deep saliva/sputum. There is a wide range of commercially available saliva collection devices but given the high sampling demand and limited stocks of swabs, 1-3 mL of unstimulated whole saliva expectorated into a sterile urine container or 50 mL conical tube is the easiest and most reliable sample to collect, unless the patient is a hyposalivator or intubated.

For an intubated patient, young child, or elderly person pipetted saliva or oral swab placed in 1 mL viral transport media (VTM) will suffice (17, 20) . Saliva should always be collected before or 30-60 minutes after eating, drinking, smoking or chewing gum with the mouth rinsed with water prior to collection to void the mouth of debris (21) . If a patient is having difficulty salivating rubbing the outside of the cheek may help. As sample positivity is essential in hospitalized patients, due to the effect of diurnal variation on levels of salivary biomarkers, two studies collected saliva first thing in the morning prior to food or brushing of teeth (14, 15) . The other studies did not account for circadian rhythm, but found the viral load to be highest in saliva for the first week after the onset of symptoms, suggesting that adequate salivary samples can be collected at anytime. However, due to salivary enzymes, it is essential, especially if samples require transportation, that whole saliva be chilled immediately after collection (e.g. shipped on ice packs)

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.09.20096354 doi: medRxiv preprint or stored in a commercial stabilizer (e.g. RNAlater and VTM) and extracted as soon as possible (12, 22) . 

In conclusion, saliva can be used to detect SARS-CoV-2 in both symptomatic patients and asymptomatic carriers. Studies to date have shown that viral loads in saliva are comparable or higher than in NPS after the onset of symptoms and remain detectable in saliva after respiratory symptoms dissipate and NPS test negative. However, due to salivary enzymes, samples must be handled correctly and processed in a timely manner. Well conducted diagnostic accuracy studies are desperately needed to validate the use of saliva for the diagnosis of COVID-19.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.09.20096354 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.09.20096354 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 13, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 13, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 13, 2020. 

• Saliva -1-3 mL drooled unstimulated saliva in a sterile urine cup or 50mL conical tube • Oral swab placed in 1 mL VTM or PBS (children, elderly, hyposalivators) • Pipetted saliva from intubated patients • Note: Collect before or 30-60 minutes after eating, drinking, smoking or chewing gum.

Rinse mouth water before collection to void the mouth of debris and excess muscin. If patient has difficulty producing saliva have them rub cheeks to induce salivation.

• Saliva -chill and transport as soon as possible on ice packs 

• Any validated RT-rtPCR assay for SARS-CoV-2

• Whole genome sequencing can also be performed on positives . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.09.20096354 doi: medRxiv preprint • The viral loads of the first confirmed case were 3.3 × 10 6 copies/mL in the pooled nasopharyngeal and throat swabs, whereas 5.9 × 10 6 copies/mL in saliva on the same day. RNA Target: S gene • In the first study, after days of medical treatments 53.3% were oral swabs positive, 27% were anal swabs positive, and 40% were serum positive. • In the second study, at day 0, 80% of positives came from oral swabs, but on day 5, 75% anal swabs and 50% oral swabs were positive. Possible shift in virus location as disease progresses.

NPS=nasopharyngeal swabs, OPS=oropharyngeal swabs, BAL=bronchoalveolar lavage, RT-PCR=reverse transcription polymerase chain reaction, RT-qPCR=quantitative reverse transcription polymerase chain reaction

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

China Novel Coronavirus I, Research T. 2020. A Novel Coronavirus from Patients with Pneumonia in China

Coronaviridae Study Group of the International Committee on Taxonomy of V. 2020. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Detection of SARS-CoV-2 RNA and Antibodies in Diverse Samples: Protocol to Validate the Sufficiency of Provider-Observed, Home-Collected Blood, Saliva, and Oropharyngeal Samples

Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia

Human Saliva Collection Devices for Proteomics: An Update

Consistent detection of 2019 novel coronavirus in saliva

Saliva: potential diagnostic value and transmission of 2019-nCoV

Human Saliva: Non-Invasive Fluid for Detecting Novel Coronavirus (2019-nCoV)

Detecting DNA viruses in oral fluids: evaluation of collection and storage methods

Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Self-Collected Oral Fluid and Nasal Swabs Demonstrate Comparable Sensitivity to Clinician Collected Nasopharyngeal Swabs for Covid-19 Detection

Salivary biomarkers: toward future clinical and diagnostic utilities

Collection, storage, and processing of saliva samples for downstream molecular applications

Rapid Design of a Bait Capture Platform for Culture-and Amplification-Free Next-Generation Sequencing of SARS-CoV-2

Department of Health and Human Services Food and Drug Administration Center for 26

Two cases of COVID-19 with positive salivary and negative pharyngeal or respiratory swabs at hospital discharge: a rising concern

Detection of 2019-nCoV in Saliva and Characterization of Oral Symptoms in COVID-19 Patients

Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2